首页> 外文期刊>Liver international : >Protective effect of Bifidobacterium pseudocatenulatum CECT7765 against induced bacterial antigen translocation in experimental cirrhosis
【24h】

Protective effect of Bifidobacterium pseudocatenulatum CECT7765 against induced bacterial antigen translocation in experimental cirrhosis

机译:伪双歧杆菌CECT7765对实验性肝硬化诱导的细菌抗原易位的保护作用

获取原文
获取原文并翻译 | 示例
           

摘要

Background & Aims: Intervention in the gut ecosystem is considered as a potential strategy to treat liver diseases and their complications. We have evaluated the effects of Bifidobacterium pseudocatenulatum CECT7765 on bacterial translocation and the liver status in experimental cirrhosis. Animals & Methods: Liver damage was induced in Balb/c mice by weight-controlled oral administration of carbon tetrachloride. Laparotomies were performed at week 12. One week prior to laparotomy, animals received B. pseudocatenulatum CECT7765 (109cfu/daily) or placebo intragastrically. All animals received Escherichia coli (107cfu/single dose) intragastrically 24 hours before laparotomy. A group of na?ve non-treated animals was included as control. Liver tissue specimens, mesenteric lymph nodes, intestinal content and blood were collected. Liver histology, profibrogenic genes expression, bacterial DNA translocation, serum endotoxaemia and liver cytokine levels were measured. Results: Bifidobacterium pseudocatenulatum CECT7765 showed no significant effect on structural liver damage, as determined by histological evaluation, alpha-smooth muscle actin distribution, profibrogenic gene expression levels, total hydroxyproline levels and malon dialdehyde production compared with mice receiving placebo. Interestingly, bacterial DNA translocation and serum endotoxin levels were significantly decreased in mice receiving the Bifidobacterium strain compared with placebo. Gut barrier integrity markers were up-regulated in mice receiving B. pseudocatenulatum CECT7765 and quantitatively correlated with intestinal gene copy numbers of the bifidobacterial strain. Gene expression levels of several anti-inflammatory mediators were also increased in mice receiving B. pseudocatenulatum CECT7765 compared with placebo. Conclusion: Oral administration of B. pseudocatenulatum CECT7765 is associated with improved gut barrier integrity and shows a beneficial effect against induced bacterial antigen translocation in the CCl4-model of cirrhosis.
机译:背景与目的:干预肠道生态系统被认为是治疗肝病及其并发症的一种潜在策略。我们评估了实验性肝硬化中假双歧双歧杆菌CECT7765对细菌易位和肝脏状态的影响。动物与方法:通过体重控制的口服四氯化碳对Balb / c小鼠引起肝损害。在第12周进行剖腹手术。在剖腹手术之前的一周,动物接受胃内的假性巴氏芽孢杆菌CECT7765(每日109cfu)或安慰剂。在剖腹手术前24小时,所有动物在胃内接受大肠杆菌(107cfu /单剂量)。一组未经处理的未经处理的动物作为对照。收集肝组织标本,肠系膜淋巴结,肠内容物和血液。测量肝脏组织学,纤维蛋白原基因表达,细菌DNA易位,血清内毒素血症和肝细胞因子水平。结果:与接受安慰剂的小鼠相比,通过组织学评估,α-平滑肌肌动蛋白分布,纤维化原基因表达水平,总羟脯氨酸水平和丙二醛产生量,伪双歧杆菌CECT7765对结构性肝损伤无明显影响。有趣的是,与安慰剂相比,接受双歧杆菌菌株的小鼠细菌DNA易位和血清内毒素水平显着降低。肠道屏障完整性标志物在接受假单胞菌CECT7765的小鼠中上调,并与双歧杆菌菌株的肠道基因拷贝数定量相关。与安慰剂相比,在接受伪catenulatum CECT7765的小鼠中几种抗炎介质的基因表达水平也有所提高。结论:假性链球芽孢杆菌CECT7765的口服给药可改善肠道屏障的完整性,并在肝硬化的CCl4模型中显示出对诱导的细菌抗原易位的有益作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号